NorthStar inks Ac-225 supply deal with Clovis

By staff writers

July 21, 2022 -- NorthStar Medical Radioisotopes has signed a long-term supply agreement with Clovis Oncology for NorthStar's actinium-225 (Ac-225) therapeutic radioisotope.

Under the terms of the deal, NorthStar will provide Clovis with its no-carrier-added Ac-225. Clovis will use Ac-255 to radiolabel its peptide-targeted radionuclide therapeutic candidate, FAP-2286, which is in development and targets fibroblast activation protein (FAP).

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking